FDA approves bedaquiline as part of therapy for pulmonary tuberculosis

News
Article

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

FDA approves bedaquiline as part of therapy for pulmonary tuberculosis | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves bedaquiline as part of therapy for pulmonary tuberculosis | Image Credit: © Calin - © Calin - stock.adobe.com.

The FDA has issued a traditional approval for bedaquiline (SIRTURO; Johnson & Johnson) to be a part of combination therapy for individuals aged 5 years and older with pulmonary tuberculosis (TB) because of Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid.

According to a press release from Johnson & Johnson, label restrictions that were included when the medicine was granted accelerated approval in 2012 are now removed.

The decision was supported by data resulting from the phase 3, STREAM Stage 2 study (NCT02409290), a large-scale, randomized, multi-country, open-label study that evaluated safety and efficacy of an all-oral bedaquiline-containing regimen for treatment of MDR-TB. Results demonstrated that the regimen "offered a significant improvement in treatment outcomes compared to injectable-containing regimens," stated Johnson & Johnson in a press release.

Granted accelerated approval by the FDA in December 2012, a supplemental New Drug Application for bedaquiline was submitted to the FDA in August 2023 to support traditional approval.

According to Johnson & Johnson, bedaquiline should not be used for the treatment of latent infection because of Mycobacterium tuberculosis, drug-sensitive pulmonary or extra-pulmonary TB, or to treat infections caused by non-TB mycobacteria.

Reference:

Johnson & Johnson receives approval from US FDA and European Commission for SIRTURO (bedaquiline). Johnson & Johnson. Press release. July 2, 2024. Accessed July 3, 2024. https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-approval-from-u-s-fda-and-european-commission-for-sirturo-bedaquiline

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Related Content
© 2025 MJH Life Sciences

All rights reserved.